OLX10212 New Zealand Phase 2a Trial Application Approved on Re-review After Rejection
The New Zealand ethics committee approved on Nov 10, 2026 on re-review the OLX10212 Phase 2a application it had rejected on Oct 12, 2026.
226950 · KOSDAQ · Based on DART filings
1 total · 20 per page
The New Zealand ethics committee approved on Nov 10, 2026 on re-review the OLX10212 Phase 2a application it had rejected on Oct 12, 2026.
Get app alerts for new disclosures from OliX Pharmaceuticals, Inc..